Effects of GH and insulin-like growth factor-I on body composition

Journal of Endocrinological Investigation

Volumn 26, Issue 9, 2003, Pages 823-831

  Svensson, Johan ^a   Lonn L ^a   Johannsson, G ^a   Bengtsson, B A ^a  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Body fat; GH; Insulin like growth factor I body composition; Lean body mass

Indexed keywords

ESTROGEN; GROWTH HORMONE; INSULIN; SOMATOMEDIN C; TESTOSTERONE;

ARM EDEMA; ARTHRALGIA; BODY COMPOSITION; BODY FAT; BODY WATER; CARPAL TUNNEL SYNDROME; CLINICAL TRIAL; DRUG ANTAGONISM; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG MEGADOSE; DRUG SENSITIVITY; EDEMA; GENDER; GROWTH HORMONE DEFICIENCY; HORMONE SUBSTITUTION; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; JOINT STIFFNESS; LEAN BODY WEIGHT; LEG EDEMA; MUSCLE STIFFNESS; MUSCLE STRENGTH; PARESTHESIA; PROTEIN BLOOD LEVEL; REVIEW; SEX DIFFERENCE;

EID: 0346968169     PISSN: 03914097     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03345231     Document Type: Review

References (83)

1. De Boer H, Blok G-J, Popp-Snijders C, Van Der Veen E. Diagnosis of growth hormone deficiency in adults. Lancet 1994, 343: 1645-6.
2. Carroll P, Christ E, Bengtsson B-Å, et al. Growth hormone deficiency in adulthood and the effects of growth hormone replacement: A review. J Clin Endocrinol Metab 1998, 83: 382-95.
3. Rosén T, Bengtsson B-Å. Premature mortality due to cardiovascular diseases in hypopituitarism. Lancet 1990, 336: 285-8.
4. Bülow B, Hagmar L, Mikoczy Z, Nordström C, Erfurth E. Increased cerebrovascular mortality in patients with hypopituitarism. Clin Endocrinol (Oxf) 1997, 46: 75-81.
5. Tomlinson J, Holden N, Hills R, et al. Association between premature mortality and hypopituitarism. West Midlands Prospective Hypopituitary Study Group. Lancet 2001, 357: 425-31.
6. Svensson J, Johannsson G, Bengtsson B-Å. Insulin-like growth factor-I in growth hormone-deficient adults: Relationship to population-based normal values, body composition and insulin tolerance test. Clin Endocrinol (Oxf) 1997, 46: 579-86.
7. Wuster C, Abs R, Bengtsson B-Å, et al. The influence of growth hormone deficiency, growth hormone replacement therapy, and other aspects of hypopituitarism on fracture rate and bone mineral density. J Bone Mineral Res 2001, 16: 398-405.
8. Bruce Å, Andersson M, Arvidsson B, Isaksson B. Body composition. Prediction of normal body potassium, body water and body fat in adults on the basis of body height, body weight and age. Scand J Clin Lab Invest 1980, 40: 461-73.
9. 40K. Int J Obes 1988, 12: 249-66.
10. Vartsky D, Elis K, Cohn S. In vivo quantification of body nitrogen by neutron capture prompt gamma-ray analysis. J Nucl Med 1979, 20: 1158-65.
11. 252Cf source. J Radioanal Nucl Chem 1987, 114: 181-5.
12. Royall D, Greenberg G, Allard J, Baker J, Harrsison J, Jeejeebhoj K. Critical assessment of body-composition measurements in mal-nourished subjects with Crohn's disease. The role of bioelectrical impedance analysis. Am J Clin Nutr 1994, 59: 325-30.
13. Bosaeus I, Johannsson G, Rosén T, et al. Comparison of methods to estimate body fat in growth hormone deficient adults. Clin Endocrinol (Oxf) 1996, 44: 395-402.
14. Horlick M, Arpadi S, Bethel J, et al. Bioelectrical impedance analysis models for prediction of total body water and fat-free mass in healthy and HIV-infected children and adolescents. Am J Clin Nutr 2002, 76: 991-9.
15. Kvist H, Sjöström L, Tylén U. Adipose tissue volume determinations in women by computed tomography: Technical considerations. Int J Obes 1986, 10: 53-67.
16. 40K, and tritium. Am J Physiol 1986, 250: E736-45.
17. Rosén T, Bosaeus I, Tölli J, Lindstedt G, Bengtsson B-Å. Increased body fat mass and decreased extracellular fluid volume in adults with growth hormone deficiency. Clin Endocrinol (Oxf) 1993, 38: 63-71.
18. Bengtsson B-Å, Brummer R-J, Edén S, Bosaeus I. Body composition in acromegaly. Clin Endocrinol (Oxf) 1989, 30: 121-30.
19. Chin E, Zhou J, Bondy C. Renal growth hormone receptor gene expression: Relationship to renal insulin-like growth factor system. Endocrinology 1992, 131: 3061-6.
20. Shimomura Y, Lee M, Oku J, Bray G, Glick Z. Sodium potassium dependent ATPase in hypophysectomized rats: Response to growth hormone, triiodothyronine, and cortisone. Metabolism 1982, 31: 213-6.
21. Biglieri E. Na retention with human growth hormone. J Clin Endocrinol Metab 1961, 21: 362-70.
22. Ho K, Weissberger A. The antinatriuretic action of biosynthetic human growth hormone in man involves activation of the renin-angiotensin system. Metabolism 1990, 39: 133-7.
23. Johannson G, Sverrisdóttir Y, Ellegård L, Lundberg P, Herlitz H. Growth hormone increases extracellular volume by stimulating sodium reabsorption in the distal nephron and by preventing pressure natriuresis. J Clin Endocrinol Metab 2002, 87: 1743-9.
24. Møller J, Frandsen E, Fisker S, Jørgensen J, Christiansen J. Decreased plasma and extracellular volume in growth-hormone deficient adults and the acute and prolonged effects of GH administration - A controlled experimental study. Clin Endocrinol (Oxf) 1996, 44: 533-9.
25. Janssen Y, Deurenberg P, Roelfsema F. Using dilution techniques and multifrequency bioelectrical impedance to assess both total body water and extracellular water at baseline and during recombinant human growth hormone (GH) treatment in GH-deficient adults. J Clin Endocrinol Metab 1997, 82: 3349-55.
26. De Boer H, Blok G, Popp-Sniders C, Stuurman L, Baxter R, Van Der Veen E. Monitoring of growth hormone replacement therapy in adults, based on measurements of serum markers. J Clin Endocrinol Metab 1996, 81: 1371-7.
27. Johansson G, Rosén T, Bengtsson B-Å. Individualized dose titration of growth hormone (GH) during GH replacement in hypopituitary adults. Clin Endocrinol (Oxf) 1997, 47: 571-81.
28. Raben M, Hollenberg C. Effect of growth hormone on plasma fatty acids. J Clin Invest 1959, 38: 484-8.
29. Goodman H. Growth hormone and the metabolism of carbohydrate and lipid in adipose tissue. Ann N Y Acad Sci 1968, 148: 419-40.
30. Zachman M, Fernandez F, Tassinari D, Thakker R, Prader A. Anthropometric measurements in patients with growth hormone deficiency before treatment with human growth hormone. Eur J Pediatr 1980, 133: 277-82.
31. Bengtsson B-Å, Edén S, Lönn L, et al. Treatment of adults with growth hormone (GH) deficiency with recombinant human GH. J Clin Endocrinol Metab 1993, 76: 309-17.
32. Rosenbaum M, Gertner J, Leibel R. Effects of systemic growth hormone (GH) administration on regional adipose tissue distribution and metabolism in GH-deficient children. J Clin Endocrinol Metab 1989, 69: 1274-81.
33. Tanner J, Whitehouse R. The effect of human growth hormone on subcutaneous fat thickness in hyposomatotrophic and panhypopituitary dwarfs. J Endocrinol 1967, 39: 263-75.
34. Tanner J, Hughes P, Whitehouse R. Comparative rapidity of response of height, limb muscle and limb fat to treatment with human growth hormone in patients with and without growth hormone deficiency. Acta Endocrinol (Copenh) 1977, 84: 681-96.
35. Jørgensen JOL, Pedersen SA, Thuesen L, et al. Beneficial effect of growth hormone treatment in GH-deficient adults. Lancet 1989, i: 1221-5.
36. Salomon F, Cuneo R, Hesp R, Sönksen P. The effects of treatment with recombinant human growth hormone on body composition and metabolism in adults with growth hormone deficiency. N Engl J Med 1989, 321: 1221-5.
37. Binnerts A, Swart G, Wilson J, et al. The effects of growth hormone administration in growth hormone deficient adults on bone, protein, carbohydrate, and lipid homeostasis, as well as on body composition. Clin Endocrinol (Oxf) 1992, 37: 79-87.
38. Whitehead H, Boreman C, McIlrath E, et al. Growth hormone treatment of adults with growth hormone deficiency: Results of a 13-month placebo-controlled cross-over study. Clin Endocrinol (Oxf) 1992, 36: 45-52.
39. De Boer H, Blok G, Voerman B, Derriks P, Van Der Veen E. Changes in subcutaneous and visceral fat mass during growth hormone replacement therapy in adult men. Int J Obes Relat Metab Disord 1996, 20: 580-7.
40. Johansson J-O, Landin K, Tengborn L, Rosén T, Bengtsson B-Å. High fibrinogen and plasminogen activator inhibitor activity in growth hormone-deficient adults. Arterioscler Thromb 1994, 14: 434-7.
41. Snel Y, Brummer R-J, Doerga M, et al. Adipose tissue assessed by magnetic resonance imaging in growth hormone-deficient adults: The effect of growth hormone replacement and a comparison with control subjects. Am J Clin Nutr 1995, 61: 1290-4.
42. Brummer R, Lönn L, Grangård U, Bengtsson B-Å, Kvist H, Sjöström L. Adipose tissue and muscle volume determinations by computed tomography in acromegaly, before and one year after adenectomy. Eur J Clin Invest 1993, 23: 199-205.
43. Ter Maaten J, De Boer H, Kamp O, Stuurman L, Van Der Veen E. Long-term effects of growth hormone (GH) replacement in men with childhood-onset GH deficiency. J Clin Endocrinol Metab 1999, 84: 2373-80.
44. Lönn L, Johansson G, Sjöström L, Kvist H, Odén A, Bengtsson B-Å. Body composition and tissue distributions in growth hormone deficient adults before and after growth hormone treatment. Obesity Research 1996, 4: 45-54.
45. Beauville M, Harant I, Crampes F, et al. Effects of long-term rhGH administration in GH-deficient adults on fat cell epinephrine response. Am J Physiol 1992, 263: E467-72.
46. Götherström G, Koranyi J, Svensson J, Alpsten M, Bosæus I, Bengtsson B-Å, Johannsson G. A prospective study of five years of growth hormone (GH) replacement therapy in GH deficient adults; sustained effects on body composition, bone mass, and metabolic indices. J Clin Endocrinol Metab 2001, 86: 4657-65.
47. Cuneo R, Salomon F, Wiles C, Hesp R, Sonksen P. Growth hormone treatment in growth hormone-deficient adults. I. Effects on muscle mass and strength. J Appl Physiol 1991, 70: 688-94.
48. De Boer H, Blok G-J, Van Der Veen E. Clinical aspects of growth hormone deficiency in adults. Endocr Rev 1995, 16: 63-86.
49. Johannsson G, Grimby G, Stibrant Sunnerhagen K, Bengtsson B-Å. Two years of growth hormone (GH) treatment increase isometric and isokinetic muscle strength in GH-deficient adults. J Clin Endocrinol Metab 1997, 82: 2877-84.
50. Jørgensen J, Pedersen S, Thuesen L, et al. Long-term growth hormone treatment in growth hormone deficient adults. Acta Endocrinol (Copenh) 1991, 125: 449-53.
51. Rutherford O, Beshyah S, Johnston D. Quadriceps strength before and after growth hormone replacement in hypopituitary adults; Relationship to changes in lean body mass and IGF-I. Endocrinol Metab 1994, 1: 41-7.
52. Beshyah S, Freemantle C, Shahi M, et al. Replacement therapy with biosynthetic human growth hormone in growth hormone-deficient hypopituitary adults. Clin Endocrinol (Oxf) 1995, 42: 73-84.
53. Wallymahmed M, Foy P, Shaw D, Hutcheon R, Edwards R, MacFarane I. Quality of life, body composition and muscle strength in adult with growth hormone deficiency: The influence of growth hormone replacement therapy for up to 3 years. Clin Endocrinol (Oxf) 1997, 47: 439-46.
54. Janssen Y, Doornbos J, Roelfsema F. Changes in muscle volume, strength, and bioenergetics during recombinant human growth hormone (GH) therapy in adults with GH deficiency. J Clin Endocrinol Metab 1999, 84: 279-84.
55. Ayling C, Moreland B, Zenelli J, Schulster D. Human growth hormone treatment of hypophysectomized rats increases the proportion of type-I fibres in skeletal muscle. J Endocrinol 1989, 123: 429-35.
56. Mayoux E, Ventura-Clapier R, Timsit J, Behar-Cohen F, Hoffman D, Mercadier J. Mechanical properties of rat cardiac skinned fibers are altered by chronic growth hormone hypersecretion. Circ Res 1993, 72: 57-64.
57. Daugaard J, Laustsen J, Hansen B, Richter E. Growth hormone induces muscle fibre type transformation in growth hormone-deficient rats. Acta Physiol Scand 1998, 164: 119-26.
58. Ameredes B, Watchko J, Daood M, Rosas J, Donahoe M, Rogers R. Growth hormone restores aged diaphragm myosin composition and performance after chronic undernutrition. J Appl Physiol 1999, 87: 1253-9.
59. Lange K, Andersen J, Beyer N, et al. GH administration changes myosin heavy chain isoforms in skeletal muscle but does not augment muscle strength or hypertrophy, either alone or combined with resistance exercise training in healthy elderly men. J Clin Endocrinol Metab 2002, 87: 513-23.
60. Bottinelli R, Narici M, Pellegrino M, et al. Contractile properties and fiber type distribution of quadriceps muscles in adults with childhood-onset growth hormone deficiency. J Clin Endocrinol Metab 1997, 82: 4133-8.
61. Daugaard J, Bramnert M, Manhem P, et al. Effect of 6 months of GH replacement on myosin heavy chain composition in GH-deficient patients. Eur J Endocrinol 1999, 141: 342-9.
62. Rutherford O, Beshyah S, Schott J, Watkins Y, Johnston D. Contractile properties of the quadriceps muscle in growth hormone-deficient hypopituitary adults. Clin Sci 1995, 88: 67-71.
63. Sunnerhagen K, Hedberg M, Henning G-B, Cider Å, Svantesson U. Muscle performance in an urban population sample of 40- to 79-year-old men and women. Scand J Rehab Med 2000, 32: 159-67.
64. Taaffe D, Pruitt L, Reim J, et al. Effect of recombinant growth hormone on the muscle strength response to resistance exercise in elderly men. J Clin Endocrinol Metab 1994, 79: 1361-6.
65. Yarasheski K, Zachwieja J, Campbell J, Bier D. Effect of growth hormone and resistance exercise on muscle growth and strength in older men. Am J Physiol 1995, 268: E268-76.
66. Papadakis M, Grady D, Black D, et al. Growth hormone replacement in healthy older men improves body composition but not functional ability. Ann Intern Med 1996, 124: 708-16.
67. Welle S, Thornton C, Statt M, McHenry B. Growth hormone increases muscle mass and strength but does not rejuvenate myofibrillar protein synthesis in healthy subjects over 60 years old. J Clin Endocrinol Metab 1996, 81: 3239-43.
68. Burman P, AG. J, Siegbahn A, Vessby B, Karlsson F. Growth hormone (GH)-deficient men are more responsive to GH replacement therapy than women. J Clin Endocrinol Metab 1997, 82: 550-5.
69. Johansson A, Engström B, Ljunghall S, Karlsson F, Burman P. Gender differences in the effects of long term growth hormone (GH) treatment on bone in adults with GH deficiency. J Clin Endocrinol Metab 1999, 84: 2002-7.
70. Välimäki M, Salmela P, Salmi J, et al. Effects of 42 months of GH treatment on bone mineral density and bone turnover in GH-deficient adults. Eur J Endocrinol 1999, 140: 545-54.
71. Schwartz E, Wiedemann E, Simon S, Schiffer M. Estrogenic antagonism of metabolic effects of administered growth hormone. J Clin Endocrinol Metab 1969, 26: 1176-81.
72. Miller K, Sesmilo G, Schiller A, Schoenfeld D, Burton S, Klibanski A. Androgen deficiency in women with hypopituitarism. J Clin Endocrinol Metab 2001, 86: 561-7.
73. Johannsson G, Burman P, Wirén L, et al. Low dose dehydroepiandrosterone affects behavior in hypopituitary androgen-deficient women: A placebo-controlled trial. J Clin Endocrinol Metab 2002, 87: 2046-52.
74. Sjögren K, Liu J, Blad K, et al. Liver-derived insulin-like growth factor I (IGF-I) is the principle source of IGF-I in blood but is not required for postnatal body growth in mice. Proc Natl Acad Sci USA 1999, 96: 7088-92.
75. Sjogren K, Wallenius K, Liu J, et al. Liver-derived IGF-I is of importance for normal carbohydrate and lipid metabolism. Diabetes 2001, 50: 1539-45.
76. Tivesten A, Bollano E, Andersson I, et al. Liver-derived insulin-like growth factor-I is involved in the regulation of blood pressure in mice. Endocrinology 2002, 143: 4235-42.
77. Sjogren K, Sheng M, Moverare S, et al. Effects of liver-derived insulin-like growth factor I on bone metabolism in mice. J Bone Miner Res 2002, 17: 1977-87.
78. Ranke M, Savage M, Chatelain P, Preece M, Rosenfeld R, Wilton P. Long-term treatment of growth hormone insensitivity syndrome with IGF-I. Results of the European Multicentre Study. The Working Group on Growth Hormone Insensitivity Syndromes. Horm Res 1999, 51: 128-34.
79. Woods K, Camacho-Hübner C, Bergman R, Barter D, Clark A, Savage M. Effects of insulin-like growth factor-I (IGF-I) therapy on body composition and insulin resistance in IGF-I gene deletion. J Clin Endocrinol Metab 2000, 85: 1407-11.
80. Carroll P, Umpleby M, Alexander E, et al. Recombinant human insulin-like growth factor-I (rhIGF-I) therapy in adults with type 1 diabetes mellitus: Effects on IGFs, IGF-binding proteins, glucose levels and insulin treatment. Clin Endocrinol (Oxf) 1998, 49: 739-46.
81. Russell-Jones D, Umpleby A, Hennessy T, et al. Use of a leucine clamp to demonstrate that IGF-I actively stimulates protein synthesis in normal humans. Am J Physiol 1994, 267: E591-8.
82. Hussain M, Schmitz O, Mengel A, et al. Comparison of the effects of growth hormone and insulin-like growth factor I on substrate oxidation and on insulin sensitivity in growth hormone-deficient humans. J Clin Invest 1994, 94: 1126-33.
83. Clemmons D, Smith-Banks A, Underwood L. Reversal of diet-induced catabolism by infusion of recombinant insulin-like growth factor-I in humans. J Clin Endocrinol Metab 1992, 75: 234-8.